SCNX

distress 8/10 · high distress / dilution risk

$0.39-2%today-85% from 52w high

scienture.com4 employeesCommack, NYPharmaceutical Retailers

Revenue

pre-revenue

Liquidity

$9M

Runway

0.7 yrs

Shares 1y

+152%

Price & events

-23.5% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.5%

-5.7%

+2.1%

-6.7%

-23.5%

-81.9%

-96.8%

-99.2%

All

Overview

Market Cap: $15.85M
Enterprise Value: $11.19M
Volume: 43.31K
52 Week Range: $0.24 – $2.60
Total Shares: 40.63M
Float Shares: 32.79M
Short %: 2.47%
% Held by Insiders: 13.31%
% Held by Institutions: 3.87%
RVOL: 0.02x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 1

2025-03-04partnershipREZENOPY (Naloxone HCl Nasal Spray 10mg/0.11mL) · Exclusive commercial and supply agreement with Kindeva for US commercialization.SEC 8-K

Approved drugs (2)

ARBLILOSARTAN POTASSIUM2025 · Prescription
REZENOPYNALOXONE HYDROCHLORIDE2024 · Prescription

Capital structure — dilution & financing

Shares out: 40,630,815 · 6 offerings/1y · 1 PIPEs

2026-05-018-Kmaterial_agreement
2025-11-07424B5offering
2025-10-248-Kmaterial_agreement
2025-10-24424B5offering
2025-10-168-Kmaterial_agreement
2025-10-14424B3offering
2025-10-038-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

buy · target $2 (+284% upside) · 1 analysts

2026-02-24Maxim GroupBuy

Competitors

none identified